N. Posthuma, P. M. ter Wee, A. J. Donker, P. L. Oe, E. M. Peers and H. A. Verbrugh, “Assesement of the Effectiveness, Safety, and Biocompatibility of Icodextrin in Automated Peritoneal Dialysis. The Dextrin in APD in Amsterdam (DIANA) Group,” Peritoneal Dialysis International, Vol. 20, Suppl. 2, 2000, pp. S106-S113.

has been cited by the following article:

• TITLE: Do We Have a Biocompatible Peritoneal Dialysis Fluid?

  AUTHORS: Shadi Hassan, Batya Kristal, Khalid Khazim, Fadi Hassan, Dunia Hassan, Kamal Hassan

  KEYWORDS: Icodextrin; Amino Acids PDF; Homocyteine; Carbohydrates; Lipids; Inflammation

  JOURNAL NAME: Open Journal of Nephrology, Vol.2 No.3, September 26, 2012

  ABSTRACT: Objective: Cardiovascular disease remains the leading cause of morbidity and mortality in patients on maintenance dialysis. Diabetes mellitus, dyslipidemia, hypertension, inflammation and hyperhomocyteinemia are major cardiovascular risk factors. Aim: to evaluate the effects of Icodextrin and amino acid peritoneal dialysis fluid (AAPDF) on these major cardiovascular risk factors looking for a more biocompatible PDF formula. Methods: 24 adult stable peritoneal dialysis patients were included in the study. 12 patients received 2L Icodextrin and other 12 patients received 2L AAPDF in their dialysis prescription for 8 weeks. Results: Icodextrin decreased fasting plasma glucose (p Conclusions: A biocompatible PDF should provide not only adequate dialysis and ultrafiltration but should also improve nutritional and metabolic status, blood pressure control and reduce inflammation and plasma homocyteine.